about
A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.Safety and effectiveness of controlled-release paroxetine in routine clinical practice: results of a postmarketing surveillance study of patients with depressionGenetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs.The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.Neuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study.Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trialsHTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis.The serotonin transporter gene and effectiveness of SSRIs.Management of chronic depressive patients with residual symptoms.Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.Remifentanil in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials.Estimated cognitive decline in patients with schizophrenia: A multicenter study.Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.5-HTTLPR rs25531A > G differentially influence paroxetine and fluvoxamine antidepressant efficacy: a randomized, controlled trial.Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression MulticEffect of basic fibroblast growth factor (FGF2) gene polymorphisms on SSRIs treatment response and side effects.The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial.Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression.Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.Therapeutic Response to Paroxetine in Major Depressive Disorder Predicted by DNA Methylation.Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT.Polymorphism of rs3813034 in Serotonin Transporter Gene SLC6A4 Is Associated With the Selective Serotonin and Serotonin-Norepinephrine Reuptake Inhibitor Response in Depressive Disorder: Sequencing Analysis of SLC6A4.HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia.Association of HLA-A*31:01 Screening With the Incidence of Carbamazepine-Induced Cutaneous Adverse Reactions in a Japanese PopulationThe association of obesity and coronary artery disease genes with response to SSRIs treatment in major depressionDelirium associated with paroxetine in an elderly depressive patient: a case reportEfficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment designFactors Associated with Non-Remission in Bipolar Disorder: The Multicenter Treatment Survey for Bipolar Disorder in Psychiatric Outpatient Clinics (MUSUBI)Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3β Gene and Their Effect on Antidepressant Treatment in Major Depressive DisorderPharmacological Management of Bipolar Disorder: Japanese Expert Consensus
P50
Q34302659-131EED73-B851-4276-82A0-1527D8AD0201Q34552006-7F70C5EB-66FA-46E1-80CA-0FF8D4C3D117Q34583477-FB836856-448F-491A-B166-592313546763Q34989892-C0DF4BDB-312C-4D62-B217-C5659E10CB90Q35136063-81FDB6FD-FFAD-44BD-A5E2-FB961A0EF021Q35653883-FE200973-BAFD-436F-9393-B96F4A0F23E6Q35715254-120FD421-8778-4975-8528-2D6FE7908636Q36033253-44CCBA57-4751-4521-8D64-C77CD6597166Q36325773-9ABB058C-F632-47B5-943B-9EBEDDF43BCFQ36380157-C238E938-209B-42E1-8750-852A2490CCA2Q36950578-FB5AD8B6-EE0C-4073-8B64-E6E1FA854AB9Q37035245-48D7C4CC-F7B7-40C6-A62B-0D759FC6FFD9Q38109593-170C5F38-BB81-4414-BF3A-5DE670763FBFQ38125219-FE2D8505-1957-4759-A78C-A9D3858A548DQ38715407-60EEE1CF-2BA2-4B2E-8803-F1A3723EA3C8Q38799951-EDBAE500-4125-4FA6-BAC5-BA6E3F9F258EQ40898013-33BB18BA-C1B8-4DAA-B9AA-AC4282A519E0Q43857736-2E098479-599C-4EC7-8ECD-0BFB84BAB756Q44900688-1D2842C5-11EC-46D9-B80C-2EFF37737561Q45935319-DC978656-777F-449D-BBFD-D38DE66B90EFQ45985388-2D3CC675-A536-42B9-9316-7961C868AFD9Q46423759-BA83D5EE-43CC-450C-BA3A-6AABB8EBE6DCQ46592697-81F37B94-CA1D-4818-99A8-6425F8C33265Q46708597-42F894D6-2E2D-47CC-B056-CBD342C22E07Q46714628-035FC686-6A2E-4894-9C3E-06EB3353FD5FQ47710405-A2C0371F-BC33-4C0B-802D-DDF8B565862BQ47966192-60E8E9F5-55BC-4008-A99C-1F80E08025F8Q48068498-31F302F5-E96D-4D35-BDBA-B428A1590631Q48087061-55DE7D41-5C78-43EE-AE6D-2C32A55FF8A1Q57557226-C551A329-5E63-40FE-B4BF-FD144C01FC7AQ64118925-A12C8BBD-09F9-4F52-AA3B-51855C82CCF6Q81306101-4E31BD08-B781-4F13-8C35-0E95060959C0Q91543237-19405360-57F4-45A2-9DFD-E2DD0EC32A1BQ91839634-F779E9AC-9FD5-4109-B542-67CE1E6BAF77Q92686405-0D142550-2EF0-4436-95DD-50E6961B5352Q96586399-7BA8DAFD-985D-4A7F-9495-5A2A3FCA3312
P50
description
researcher (ORCID 0000-0001-6727-7272)
@en
name
Masaki Kato
@en
type
label
Masaki Kato
@en
prefLabel
Masaki Kato
@en
P31
P496
0000-0001-6727-7272